Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis

IMPORTANCE: The log-rank test is considered the criterion standard for comparing 2 survival curves in pivotal registrational trials. However, with novel immunotherapies that often violate the proportional hazards assumptions over time, log-rank can lose power and may fail to detect treatment benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukhopadhyay, Pralay, Ye, Jiabu, Anderson, Keaven M., Roychoudhury, Satrajit, Rubin, Eric H., Halabi, Susan, Chappell, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305601/
https://www.ncbi.nlm.nih.gov/pubmed/35862037
http://dx.doi.org/10.1001/jamaoncol.2022.2666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305601/
https://www.ncbi.nlm.nih.gov/pubmed/35862037
http://dx.doi.org/10.1001/jamaoncol.2022.2666

Ejemplares similares